Clinical Trial Update: Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating a recombinant EphB4-HSA fusion protein in combination with standard chemotherapy for advanced or metastatic solid tumors; the study is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Gallbladder Cancer
• Head and Neck Squamous Cell Carcinoma
• Non-small Cell Lung Cancer
• Pancreatic Adenocarcinoma
• Pancreatic Cancer

Drugs mentioned

• EphB4-HSA fusion protein (recombinant EphB4-HSA fusion protein)

Snippet

Sponsor: University of Southern California | Conditions: Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING